Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Finding Study of CycloSam (153Sm-DOTMP) Combined With External Beam Radiotherapy to Treat High Risk Osteosarcoma and Other Solid Tumors Metastatic to Bone

Next Previous
Trial Profile

A Dose Finding Study of CycloSam (153Sm-DOTMP) Combined With External Beam Radiotherapy to Treat High Risk Osteosarcoma and Other Solid Tumors Metastatic to Bone

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Samarium 153 DOTMP (Primary) ; Calcium carbonate; Filgrastim; Plerixafor
  • Indications Bone metastases; Osteosarcoma; Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 13 Oct 2022 Status changed from suspended to withdrawn prior to enrolment.
  • 03 Jun 2022 Status changed from not yet recruiting to suspended.
  • 03 Dec 2021 Planned initiation date changed from 1 Nov 2021 to 1 Apr 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top